The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Abstract
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumor with a relatively poor prognosis. The authors' objectives were to examine treatment utilization and factors associated with long-term survival after resection of ACC in a large, national, patient population. METHODS: Patients diagnosed with ACC from 1985 to 2005 were identified from the National Cancer Data Base (NCDB). Patient, tumor, treatment, and hospital factors associated with survival after resection were examined. RESULTS: For the current study, 3982 patients with ACC were identified. Median age at diagnosis was 55 years. Median tumor size was 13 cm. Of the patients with nodes examined, 26.5% had nodal metastases. Distant metastases were found on presentation in 21.6% of patients. A total of 57.4% of patients underwent surgical resection alone, whereas 16.0% underwent resection with adjuvant chemotherapy or radiation. A total of 19.4% had margin-positive resections. Treatment utilization remained unchanged from 1985 to 2005 (P = .28). Median follow-up was 24 months. Overall 5-year survival for all patients who underwent resection was 38.6% (median survival, 31.9 months). Multivariable analysis demonstrated a higher risk of death with increasing age, poorly differentiated tumors, involved margins, and nodal or distant metastases. Overall survival remained unchanged from 1985 to 2000 (P = .08). CONCLUSIONS: ACC carries a poor prognosis for patients commonly presenting with large, locally invasive tumors, involved margins, and metastatic disease. Survival is not affected by size but is diminished with increasing age, poorly differentiated tumors, involved margins, and the presence of regional and distant disease. Identification of novel therapies may help to increase survival, which has remained unchanged over the last 20 years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Analysis of the SEER database gives a slightly older mean age of 55 years (11).”
From Adrenocortical carcinoma (2014) · cites this paper as [11]
In the citing paper
“However, in the United States, 45% of adrenalectomies for ACC are performed in community hospitals, 30% in academic centers, and only 15% in National Cancer Institute-designated Cancer Centers, suboptimal treatment of a rare and aggressive disease requiring specialized knowledge of surgical technique (11).”
From Adrenocortical carcinoma (2014) · cites this paper as [11]
In the citing paper
“an analysis of almost 4000 patients from the National Cancer Data Base, which found that 9% of ACC patients treated with surgery had microscopically positive margins (R1), whereas a further 10% had macroscopically positive margins (R2) (11).”
From Adrenocortical carcinoma (2014) · cites this paper as [11]
In the citing paper
“The outcomes after surgical resection alone have remained suboptimal (11, 244, 267, 269–273).”
From Adrenocortical carcinoma (2014) · cites this paper as [11]
In the citing paper
“patients with positive margins had a dismal prognosis compared with those with uninvolved margins; 5-year survival was 10% after R2 resection, 21% after R1, and 49% after R0 (11).”
From Adrenocortical carcinoma (2014) · cites this paper as [11]
In the citing paper
“ACC has a well-documented propensity for lymphatic dissemination (11, 91, 351), with involved nodal disease in approximately 15% to 27% of patients at the time of surgery (11, 91).”
From Adrenocortical carcinoma (2014) · cites this paper as [11]
In the citing paper
“In the United States, it is used in approximately 10% of cases, according to analyses of both the National Cancer Data Base and the SEER program (4, 11, 90).”
From Adrenocortical carcinoma (2014) · cites this paper as [11]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10 · Cited by 2,097
Spiess, P. E., Lee, A. K., Leibovici, D., Wang, X., Do, K.-A., & Pisters, L. L. (2006) · Cancer · doi:10.1002/cncr.21979 · Cited by 1,930
The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States
Bilimoria, K. Y., Stewart, A. K., Winchester, D. P., & Ko, C. Y. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9747-3 · Cited by 1,853
Self-citationComparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759
Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew, E., Reiff, E., Duh, Q., Clark, O. H., & McMillan, A. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0329-x · Cited by 451
Self-citationManagement of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421
Dackiw, A. P. B., Lee, J. E., Gagel, R. F., & Evans, D. B. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0030-7 · Cited by 390
Schulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366
An eleven-year experience with adrenocortical carcinoma.
Pommier, R. F., & Brennan, M. F. (1992) · PubMed · Cited by 332
Kendrick, M. L. (2001) · Archives of Surgery · doi:10.1001/archsurg.136.5.543 · Cited by 140
Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope
Kirschner, L. S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1739 · Cited by 107
Outcomes of adrenal cortical carcinoma in the United States
Paton, B. L., Novitsky, Y. W., Zerey, M., Harrell, A. G., Norton, H. J., Asbun, H., Kercher, K. W., & Heniford, B. T. (2006) · Surgery · doi:10.1016/j.surg.2006.07.035 · Cited by 97
Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma
Gonzalez, R. J., Tamm, E. P., Ng, C., Phan, A. T., Vassilopoulou-Sellin, R., Perrier, N. D., Evans, D. B., & Lee, J. E. (2007) · Surgery · doi:10.1016/j.surg.2007.09.006 · Cited by 84
Jensen, J. C. (1991) · Archives of Surgery · doi:10.1001/archsurg.1991.01410280059008 · Cited by 81
Decker, R. A., Elson, P. J., Hogan, T. F., Citrin, D. L., Westring, D. W., Banerjee, T. K., Gilchrist, K. W., & Horton, J. (1991) · PubMed · Cited by 77
Adrenal Cortical Carcinoma—Review of Current Knowledge and Treatment Practices
Phan, A. T. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.04.007 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 3
- 1990, International Classification of Disease for Oncology
- 2000, International Classification of Disease for Oncology
- 2004, Facility Oncology Registry Data Standards
Cited by
Sorted by citations
Faßnacht, M., Dekkers, O. M., Else, T., Baudin, É., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assié, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 976
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., Lerario, A. M., Else, T., Knijnenburg, T. A., Ciriello, G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.002 · Cited by 657
Self-citationFaßnacht, M., Assié, G., Baudin, É., Eisenhofer, G., de la Fouchardière, C., Haak, H. R., de Krijger, R. R., Porpiglia, F., Terzolo, M., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2099 · Cited by 446
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Metadata
- Authors
- Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C.
- Affiliations
- Northwestern University (US)
- University of California, San Francisco (US)
- Corresponding author
- Bilimoria, Karl Y.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-10-30
- Volume
- 113
- Issue
- 11
- Pages
- 3130-3136
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1994325777
- Cited by
- 493
- References
- 22
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 29 · 2023: 28 · 2022: 28 · 2021: 45 · 2020: 39 · 2019: 29 · 2018: 39 · 2017: 31 · 2016: 26 · 2015: 35 · 2014: 24 · 2013: 19 · 2012: 29
- FWCI
- 17.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- adrenocortical carcinoma, adrenalectomy, surgical resection, long-term survival, prognostic factors, tumor differentiation, positive resection margins, lymph node metastasis, distant metastasis, adjuvant chemotherapy, adjuvant radiotherapy, treatment utilization, age at diagnosis
- MeSH terms
- Adrenal Cortex Neoplasms, Adult, Aged, Female, Humans, Male, Middle Aged, Prognosis, Registries, United States, Survival Analysis, Treatment Outcome, Adrenocortical Carcinoma, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
